Open Access Repository

Baseline characteristics and age-related macular degeneration in participants of the 'ASPirin in Reducing Events in the Elderly' (ASPREE)-AMD trial

Robman, LD, Thao, LTP, Guymer, RH, Wolfe, R, Woods, RL, Hodgson, LA, Phung, J, Makeyeva, GA, Le-Pham, Y-A, Orchard, SG, Suleiman, J, Maguire, E, Trevaks, RE, Ward, SA, Riaz, M, Lacaze, P, Storey, E, Abhayaratna, WP, Nelson, MR ORCID: 0000-0001-9941-7161, Ernst, ME, Reid, CM and McNeil, JJ 2020 , 'Baseline characteristics and age-related macular degeneration in participants of the 'ASPirin in Reducing Events in the Elderly' (ASPREE)-AMD trial' , Contemporary Clinical Trials Communications, vol. 20 , pp. 1-11 , doi:

141830 - Baseli...pdf | Download (645kB)

| Preview


Purpose: To describe the baseline participant characteristics in the ASPREE-AMD study, investigating the effect of aspirin on AMD incidence and progression.Methods: Australian participants from the ASPirin in Reducing Events in the Elderly (ASPREE) trial, randomized to 100 mg aspirin daily or placebo, had non-mydriatic, digital color fundus images graded according to the Beckman AMD classification. Associations with AMD were determined for baseline characteristics and genetic risk variants.Results: ASPREE-AMD sub-study enrolled 4993 participants with gradable macular images. Median age was 73.4 years (IQR, 71.5, 76.6), 52% were female, 10% had diabetes mellitus, 73% had hypertension, and 44% were former/current smokers. Early, intermediate and late AMD (detected in 20.6%, 16.1%, 1.1%, respectively), significantly associated with age, were also associated with increasing HDL levels: OR = 1.52 (95%CI, 1.26, 1.84), OR = 1.43 (1.17, 1.77) and OR = 1.96 (1.02, 3.76), respectively. Female sex was associated with early [OR = 1.37 (1.16, 1.62)], and intermediate [OR = 1.35 (1.12, 1.63)] AMD, as was previous regular use of aspirin, with OR = 1.46 (1.11, 1.92) and OR = 1.37 (1.01, 1.85), respectively. Current smoking had increased odds for late AMD, OR = 4.02 (1.42, 11.36). Genetic risk variant rs3750846 (ARMS2/HTRA1) was associated with each AMD stage (p CFH) with intermediate and late AMD (p C3) with late AMD (p Conclusions: Observed associations are typical of AMD. The ASPREE-AMD clinical trial provides a unique opportunity to determine the risks and benefits of low-dose aspirin for AMD incidence and progression in elderly population.

Item Type: Article
Authors/Creators:Robman, LD and Thao, LTP and Guymer, RH and Wolfe, R and Woods, RL and Hodgson, LA and Phung, J and Makeyeva, GA and Le-Pham, Y-A and Orchard, SG and Suleiman, J and Maguire, E and Trevaks, RE and Ward, SA and Riaz, M and Lacaze, P and Storey, E and Abhayaratna, WP and Nelson, MR and Ernst, ME and Reid, CM and McNeil, JJ
Keywords: AMD, age-related macular degeneration, aspirin, baseline characteristics, elderly, randomized controlled trial
Journal or Publication Title: Contemporary Clinical Trials Communications
Publisher: Elsevier Inc.
ISSN: 2451-8654
DOI / ID Number:
Copyright Information:

Copyright 2020 The Authors. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page